ZA200207489B - Apomorphine derivatives and methods for their use. - Google Patents

Apomorphine derivatives and methods for their use.

Info

Publication number
ZA200207489B
ZA200207489B ZA200207489A ZA200207489A ZA200207489B ZA 200207489 B ZA200207489 B ZA 200207489B ZA 200207489 A ZA200207489 A ZA 200207489A ZA 200207489 A ZA200207489 A ZA 200207489A ZA 200207489 B ZA200207489 B ZA 200207489B
Authority
ZA
South Africa
Prior art keywords
methods
apomorphine derivatives
apomorphine
derivatives
Prior art date
Application number
ZA200207489A
Other languages
English (en)
Inventor
Pramod K Gupta
Deborah Milkowski
Debra Sutkowski-Markham
Original Assignee
Tap Pharmaceutical Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tap Pharmaceutical Prod Inc filed Critical Tap Pharmaceutical Prod Inc
Publication of ZA200207489B publication Critical patent/ZA200207489B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
ZA200207489A 2000-04-07 2002-09-18 Apomorphine derivatives and methods for their use. ZA200207489B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19565000P 2000-04-07 2000-04-07

Publications (1)

Publication Number Publication Date
ZA200207489B true ZA200207489B (en) 2003-12-18

Family

ID=22722192

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200207489A ZA200207489B (en) 2000-04-07 2002-09-18 Apomorphine derivatives and methods for their use.

Country Status (18)

Country Link
US (1) US6506765B2 (enExample)
EP (1) EP1284735A4 (enExample)
JP (1) JP2003532640A (enExample)
KR (1) KR20030036157A (enExample)
CN (1) CN1471395A (enExample)
AU (1) AU2001255818A1 (enExample)
BG (1) BG107217A (enExample)
BR (1) BR0109515A (enExample)
CA (1) CA2405419A1 (enExample)
CZ (1) CZ20023637A3 (enExample)
HU (1) HUP0301773A3 (enExample)
IL (1) IL151614A0 (enExample)
MX (1) MXPA02009904A (enExample)
NO (1) NO20024806D0 (enExample)
PL (1) PL361672A1 (enExample)
SK (1) SK15772002A3 (enExample)
WO (1) WO2001076602A1 (enExample)
ZA (1) ZA200207489B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
JP2005526790A (ja) * 2002-03-19 2005-09-08 ミシェル ホリック アポモルフィンおよび類縁体の配糖体およびオルトエステル配糖体誘導体、ならびにそれらの使用方法
WO2004069167A2 (en) * 2003-01-31 2004-08-19 Nastech Pharmaceutical Company Inc. Method and compositions for treating male infertility
US20060178394A1 (en) * 2003-04-14 2006-08-10 Staniforth John N Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
RS52671B (sr) 2005-10-12 2013-06-28 Unimed Pharmaceuticals Llc Poboljšani gel testosterona i postupak korišćenja
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
PT3713933T (pt) 2017-11-24 2026-05-19 H Lundbeck As Novos profrmacos de catecolamina para utilizao no tratamento de doena de parkinson
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US12391650B2 (en) 2019-05-21 2025-08-19 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's disease
JP7641234B2 (ja) 2019-05-21 2025-03-06 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
EP3972600B1 (en) 2019-05-21 2026-02-18 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
WO2020234275A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
WO2023012736A1 (en) * 2021-08-05 2023-02-09 Zydus Lifesciences Limited Stable pharmaceutical compositions of apomorphine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
DE69434304T2 (de) 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
ATE312609T1 (de) 1994-04-22 2005-12-15 Pentech Pharmaceuticals Inc Sublinguale zusammensetzung enthaltend apomorphine zur diagnose der funktionellen impotenz
US5562917A (en) 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
PT914097E (pt) 1996-03-12 2002-06-28 Alza Corp Composicao e forma de dosagem compreendendo antagonista de opioide
GB9700878D0 (en) 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US5925629A (en) * 1997-10-28 1999-07-20 Vivus, Incorporated Transurethral administration of androgenic agents for the treatment of erectile dysfunction
WO1999027905A1 (en) 1997-12-02 1999-06-10 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions for nasal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
EP1089736A2 (en) * 1998-06-22 2001-04-11 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
IT1299566B1 (it) * 1998-07-17 2000-03-16 Ifi Istituto Farmacoterapico I Cerotto transdermico e composizioni farmaceutiche comprendenti r (-)- norapropilapomorfina cloridrato e/o s (+) - norapropilapomorfina
US5994363A (en) 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
EP1175206A1 (en) * 1999-05-13 2002-01-30 Unihart Corporation Pharmaceutical compositions comprising apocodeine and/or its derivatives

Also Published As

Publication number Publication date
NO20024806D0 (no) 2002-10-04
BG107217A (bg) 2003-05-30
US20020002176A1 (en) 2002-01-03
HUP0301773A3 (en) 2006-02-28
HUP0301773A2 (hu) 2003-09-29
MXPA02009904A (es) 2004-09-06
IL151614A0 (en) 2003-04-10
CZ20023637A3 (cs) 2003-02-12
SK15772002A3 (sk) 2003-09-11
CN1471395A (zh) 2004-01-28
KR20030036157A (ko) 2003-05-09
WO2001076602A1 (en) 2001-10-18
JP2003532640A (ja) 2003-11-05
CA2405419A1 (en) 2001-10-18
PL361672A1 (en) 2004-10-04
AU2001255818A1 (en) 2001-10-23
US6506765B2 (en) 2003-01-14
EP1284735A4 (en) 2006-01-11
EP1284735A1 (en) 2003-02-26
BR0109515A (pt) 2004-08-10

Similar Documents

Publication Publication Date Title
ZA200203316B (en) New use and novel n-azabicyclo-amide derivatives.
IL152783A0 (en) 2-aminocarbonyl-9h-purine derivatives
HUP0301773A3 (en) Apomorphine derivatives and methods for their use
HRP20030055A2 (en) 4-phenyl-pyridine derivatives
IL150841A0 (en) 1h-imidazopyridine derivatives
MXPA03004644A (es) Derivados de fenilacetamdia-pirazol y su uso como agentes antitumorales.
AU8420301A (en) Use
MXPA03004932A (es) 2-anilino-bencimidazoles sustituidos y su uso como inhibidores de nhe.
HUP0302295A3 (en) Thienodibenzoazulene derivatives, process for their preparation and use thereof
ZA200205482B (en) Aminosulfonylbiphenyl derivatives.
GB0025788D0 (en) Use
HUP0300562A3 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the
ZA200206151B (en) Substituted amionomethyl-phenyl-cyclohexane derivatives.
AU4498201A (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment ofpain
MXPA03002737A (es) Derivados sustituidos de 1-aminobutan-3-ol.
ZA200206150B (en) Aminomethyl-phenyl-cyclohexanone derivatives.
AU2796602A (en) Coniosetin and derivatives thereof, method for producing the same and use thereof
MXPA03002734A (es) Derivados de 5-amino-1-penten-3-ol sustituidos.
GB0005070D0 (en) Use
GB0029634D0 (en) Use
IL151598A0 (en) 2-phenylpyran-4-one derivatives
IL156160A0 (en) Klainetins and their derivatives, method for their preparation and use thereof
GB0007510D0 (en) D.o.t.t.s
AU4240401A (en) Pluraflavins and derivatives thereof, process for their preparation and use thereof
HK1054863A (en) Apomorphine derivatives and methods for their use